Wave Life Sciences启动WVE-007针对肥胖及心脏代谢疾病的Inlight™试验2a阶段

美股速递
Jun 24

Wave Life Sciences已正式启动其候选药物WVE-007(一种靶向INHBE的GalNAc-siRNA疗法)针对肥胖及心脏代谢疾病的Inlight™临床试验的2a阶段部分。该阶段的推进标志着公司在探索新型RNA疗法治疗此类复杂疾病方面迈出了关键一步。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10